NRIX240517C17500
- 0.05
- 0.000.00%
Nurix Therapeutics Newsroom
Nurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948
Nurix Therapeutics Is Maintained at Buy by Stifel
Nurix Therapeutics Is Maintained at Buy by Stifel
Express News | Stifel Maintains Buy on Nurix Therapeutics, Maintains $27 Price Target
Express News | Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Express News | Nurix Therapeutics Announces Upcoming Oral Presentation of New Data From Ongoing Clinical Trial of Nx-5948, a Selective Bruton’s Tyrosine Kinase (Btk) Degrader, at the European Hematology Association Congress (Eha2024)
Express News | Nurix Therapeutics Inc : Stephens Initiates Coverage With Overweight Rating; Price Target $20
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Express News | Stephens & Co. Initiates Coverage On Nurix Therapeutics With Overweight Rating, Announces Price Target of $20
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 42.76% Stephens & Co. → $20 Initiates Coverage On → Overweight 04/11/2024 64.17% RBC Capital $2
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat
Nurix Therapeutics(NRIX.US) Officer Sells US$44,878.17 in Common Stock
$Nurix Therapeutics(NRIX.US)$ Officer van Houte Hans sold 3,499 shares of common stock on May 2, 2024 at an average price of $12.826 for a total value of $44,878.17.Source: Announcement What is statem
Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Nurix Therapeutics (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Express News | Nurix Therapeutics Shares Are Trading Lower After the Company Priced an Upsized Public Offering of 10,166,667 Shares of Common Stock at $15 per Share
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both inactive. Nurix Therapeutics (NRIX) stock was down more tha
Sector Update: Health Care
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) both inactive. Nurix Therapeutics (NRIX) stock was down nearly 5
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ:APLD) fell sharply in today's pre-market trading after